Document is current
Any future updates will be listed below
-
Authors
Primac, Irina https://orcid.org/0000-0001-7989-5027
Tabury, Kevin https://orcid.org/0000-0002-8004-3718
Tasdogan, Alpaslan https://orcid.org/0000-0003-2543-852X
Baatout, Sarah
Herrmann, Ken https://orcid.org/0000-0002-9662-7259
- License Information
-
More Information
Article History
Accepted: 4 August 2025
First Online: 9 September 2025
Competing interests
: A.T. has received honoraria as a speaker from Danone and MSD. K.H. has received consultant fees from Actithera, Advanced Accelerator Applications, a Novartis company, Amgen, AstraZeneca, Bain Capital, Bayer, Boston Scientific, Convergent, Curium, Debiopharm, EcoR1, Fusion, GE Healthcare, Immedica, Isotopen Technologien München, Janssen, Merck, Molecular Partners, MSD, NVision, Pentixapharm, Pfizer, POINT Biopharma, Radiopharm Theranostics, Rhine Pharma, Siemens Healthineers, Sofie Biosciences, Telix, Theragnostics and Ymabs; research grants from Advanced Accelerator Applications, a Novartis company, Boston Scientific and Janssen; and has stock or other ownership interests with AdvanCell, Aktis Oncology, Convergent, NVision, Sofie Biosciences and Yellowbird Diagnostics. I.P., K.T. and S.B. declare no competing interests.
